Splanchnic Vein Thrombosis and MTHFR Mutation
Jaouad Yousfi1, Fatimazahra Bensalek1, Latifa Benjilali1, Lamiaa Essaadouni2
1Department of Internal Medicine, University Hospital of Mohammed VI, Marrakesh, Morocco

DOI: 10.36348/sjm.2021.x06d04.001 | Received: 13.03.2021 | Accepted: 17.04.2021 | Published: 25.04.2021
*Corresponding Author: Jaouad Yousfi

Abstract
Non-cirrhotic portal vein thrombosis is a rare condition. Constitutional thrombophilia, alone or with other risk factors, predisposes to splanchnic thrombosis. Methylenetetrahydrofolate reductase (MTHFR) mutations are associated with vascular diseases. We report an observation of a 48-year-old patient who was diagnosed with MTHFR mutation during the etiological workup of a mesenteric venous thrombosis.

Keywords: Portal thrombosis- MTHFR mutation –thrombophilia.

INTRODUCTION
In 1995, Froost et al., described the MTHFR gene, located on chromosome 1, whose mutation induces three genotypes: CC (wild type), CT (heterozygous) and TT (homozygous). This mutation causes an alteration in the conversion of homocysteine to methionine, leading to its accumulation, and therefore be responsible for a mild to moderate hyperhomocysteinemia. Elevated plasma homocysteine levels increase the secretion of endothelin-1, cause endothelial cell injury, and decrease the secretion of endothelium-derived relaxing factors and prostaglandin, which leads to thromboembolic complications [1].

CASE PRESENTATION
A 48-year-old man presented with epigastric abdominal pain. The clinical examination found tenderness of the epigastrium, an anal fissure, without any hepatosplenomegaly. Abdominal ultrasound showed mesenteric venous thrombosis.

The biological assessment showed a biological inflammatory syndrome (C-reactive protein at 69.67 mg/l, erythrocyte sedimentation rate at 65 mm). The patient had negative serologies for brucellosis, leishmaniasis, hepatitis B and C. The haemogram and the bone marrow biopsy were normaland the JAK2 V617F mutation was not detected. The screening for anti-nuclear, anti-cardiolipins, anti-B2 glycoproteins Iantibodies and lupus anticoagulant was negative.

The constitutional thrombophilia assessment did not show protein C or S deficiency (Protein C at 106% (80-130) and Protein S at 60% (70-130)), nor was it the case for factor V Leiden and factor II mutations. The factor VIII was at 86% (70-140) and the antithrombin III was at 85% (80-120). The serum homocysteine level was high at 16.48 µmol (<10). He also had MTHFR C677T heterozygous mutation.

The patient was treated with anticoagulants: low molecular weight heparin followed by rivaroxaban 20 mg daily.

The 3 months follow-up showed clinical and biological improvement. The C-reactive protein was at 8.76 mg/l (vs 69.67 on admission), and the abdominal palpation was normal. No bleeding events were observed.

DISCUSSION
Portalvein thrombosis (PVT) is a relatively common complication in cirrhotic patients, with a prevalence that varies between 0.6 and 26% [2, 3].

PVT can also occur in absence of an overt liver disease, due to locoregional (70 of cases %), and general aetologies (30%) [4].

Constitutional prothrombotic disorders such as antithrombin III, protein C and S deficiency, the factor V Leiden mutation, hyperhomocysteinemia and MTHFR mutation contribute to thrombotic manifestations such as PVT [5].

Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of the folate pathway. The presence of its mutation alters folate metabolism and induces a moderate increase in the plasma homocysteine concentrations. Moderate hyperhomocysteinemia is considered by most authors to be a vascular risk factor for both arterial and venous disease. The MTHFR C677T and A1298 Cpolyorphism gene mutation is associated with thromboembolic disease in homozygous and heterozygous carriers, with even normal blood homocysteine levels [6, 7].

According to three prospective studies, the presence of a homozygous or heterozygous MTHFR mutation represents a thromboembolic risk factor in cirrhotic and non-cirrhotic patients. Where as in the same patients, the role of the factor Vleiden and prothrombin mutation is less important [8-10].

The MTHFR mutation is also implicated in the occurrence of thrombosis at other sites. According to Ely, in a series of 34 cases of severe pulmonary embolism, 8 cases of MTHFR mutation were found (1 homozygous, 7 heterozygous) [3].

Rozen et al., reported that the MTHFR C677T mutation (homozygous or heterozygous) seems to increase the risk of cerebral venous thrombosis or pulmonary embolism in the presence of other risk factors [11, 12].

**CONCLUSION**

The etiological workup of non-cirrhotic portal veinous thrombosis should be exhaustive and must include the search for the MTHFR mutation which is a genetic thromboembolic risk factor with or without hyperhomocysteinemia.

**REFERENCES**


